Development of targeted therapies such as EGFR‐TKIs has revolutionized the management of EGFR‐mutant LUAD patients.5, 6 Furthermore, pemetrexed7 and bevacizumab8 were approved for nonsquamous NSCLC. Here, EGFR is linked to non-small cell lung carcinoma.